2. UroToday Home
  3. Categories

BPH - Benign Prostatic Enlargement

Clinical Outcomes of Transurethral Water Vapor Energy Therapy with Rezumᵀᴹ System.

We carefully reviewed and evaluated the efficacy of transurethral water vapor energy therapy (WAVE) with Rezumᵀᴹ system for treatment of benign prostatic hyperplasia. Between April and September 2023, 41 patients received WAVE under local anesthesia as day surgery at the outpatient department in our institution.

The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review.

Benign prostatic hyperplasia (BPH) is highly prevalent and associated with a significant impact on individuals' well-being. Initial management involves various medications, but their benefits can be limited by side effects, particularly concerning young people.

Non-surgical management of BPH: An updated review of current literature and state of the art on natural compounds and medical therapy.

Benign prostatic hyperplasia (BPH) is a common urological disease that is strongly associated with the aging process and can lead to lower urinary tract symptoms (LUTS). LUTS due to BPH can significantly affect the quality of life of many patients.

Measuring the efficacy of Serenoa repens (USPlus) extract with mobile uroflowmetry.

Benign prostatic hyperplasia (BPH) is a prevalent condition affecting a significant portion of the male population, leading to secondary lower urinary tract symptoms (LUTS). Alternative therapies such as phytotherapy using Lipidosterolic extract of Serenoa repens (LSESR USPlus) are commonly used.

Possible impact of antioxidant intake on composite dietary antioxidant index and the progression of benign prostatic hyperplasia: an observational study.

We aim to evaluate the association of composite dietary antioxidant index (CDAI) and Benign Prostatic Hyperplasia (BPH) in a large population in the United States using a cross-sectional design.

Data was retrieved from the National Health and Nutrition Examination Survey (NHANES) 2003-2008 and 2013-2020 datasets.

Burden of Benign Prostatic Hyperplasia (BPH) in Low- and Middle-Income Countries in Sub-Saharan Africa (SSA)

Background: Benign prostatic hyperplasia (BPH) is the leading cause of lower urinary tract symptoms (LUTSs) in men, with a histological prevalence that increases significantly with age. While extensive research on BPH has been conducted in high-income countries (HICs), limited information exists regarding its burden in low- and middle-income countries (LMICs), especially in Sub-Saharan Africa (SSA). Understanding the prevalence, impact on quality of life, and management practices in these regions is crucial for developing effective healthcare policies and improving patient outcomes.

Combination Prostatic Artery Embolization Prior to Water-Jet Ablation (Aquablation) for Benign Prostatic Hypertrophy: A Propensity Score Analysis.

Objectives: To compare post-operative bleeding measures in patients who underwent prostatic artery embolization (PAE) prior to water-jet ablation (aquablation) vs. water-jet ablation alone. Methods: A retrospective review identified 145 patients treated with water-jet ablation for benign prostatic hyperplasia from December 2018 to June 2021.

Public Views on Managing Benign Prostatic Hyperplasia-Related Voiding Dysfunction: Potential Applications of Digital Therapeutic.

This study aims to explore the potential of digital therapeutics in managing voiding dysfunction associated with benign prostatic hyperplasia (BPH). To achieve this, we collected and analyzed news and community data from major Korean platforms to assess the trends in media and community discussions and examine how digital therapeutics can contribute to personalized care and support self-management for patients with BPH-related voiding dysfunction.

Initial Experience of Contact Laser Vaporization of the Prostate Using the New Type of Fiber for Benign Prostatic Hyperplasia in a Single Institution.

The objective of this study is to evaluate our initial experience with contact laser vaporization of the prostate (CVP) using the new type of fiber for benign prostatic hyperplasia (BPH).

We retrospectively evaluated 43 patients in whom CVP was performed using the new type of fiber from October 2020 to December 2021 at our institution.

Analysis of the efficacy of Prostatic Artery Embolization in the treatment of Benign Prostatic Hyperplasia.

To investigate the safety and efficacy of prostatic artery embolization (PAE) in the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH), and to investigate predictors of clinical success of PAE.

Page 1 of 295